ArticleBioengineering (Basel, Switzerland)2025
Towards Wideband Characterization and Modeling of In-Body to On-Body Intrabody Communication Channels.
Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hepatic drug transporters in pharmacotherapy: mechanisms, therapeutic targeting, and clinical translation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Implantable intrabody communication (IBC) is a method that enables low-power, high-security communication between implanted in-body devices that could track biomedical signals and an on-body receiver by using the human body as a communication medium. As the human body consists of various tissues that each have different conductivity, this paper explores the effects of the conductivity of the communication medium on the channel gain over a wide frequency range from 10 MHz up to 300 MHz through the measurements and two models: an electrical circuit model and a FEM simulation model. Measurements are conducted using a liquid phantom with varying conductivity values from 0 S/m up to 1 S/m, covering most human tissues in the frequency range of interest. The circuit and FEM models are designed to mimic the measurement setup in order to verify the measurement results. Results show that the circuit model predicts the communication channel characteristics well at lower frequencies but cannot account for the influence of the measurement setup at higher frequencies. The influence of wire inductances, which can cause a resonant behavior when measuring at frequencies above 100 MHz, was observed using the FEM model. The results also show that the higher the conductivity of the tissue in which the device is implanted, the lower the gain of the signal, with the difference in gain being more prominent when capacitive termination with a high-impedance load is used instead of low-impedance termination. These findings provide valuable insight for selecting the appropriate interface (low-impedance vs. high-impedance termination) across specific frequency ranges for in-body to on-body (IB2OB) communication devices, while illustrating the effect of tissue conductivity on an IBC channel, thereby supporting the optimized design and implementation of reliable IB2OB communication systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.